Drug Profile


Alternative Names: ATI-7505

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Renexxion
  • Class Benzamides; Gastrokinetics; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Gastro-oesophageal reflux; Non-ulcer dyspepsia
  • Discontinued Erosive oesophagitis

Most Recent Events

  • 16 Nov 2016 Renexxion plans two phase III trials for Constipation in USA
  • 16 Nov 2016 Phase-II clinical trials in Constipation in USA (PO)
  • 16 Nov 2016 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO) (Renexxion Pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top